Baseline and treatment characteristics
| Characteristic . | All patients (n = 40) . |
|---|---|
| Baseline characteristics | |
| Age, years, median (range) | 55 (27-70) |
| Male gender, n (%) | 27 (67.5) |
| Subtype (monoclonal globulin), n (%) | |
| IgG | 17 (42.5) |
| IgA | 11 (27.5) |
| IgD | 7 (17.5) |
| Light chain | 5 (12.5) |
| ISS stage, n (%) | |
| I | 15 (37.5) |
| II | 13 (32.5) |
| III | 12 (30) |
| Previous therapy lines, median (range) | 4 (2-9) |
| CAR T-cell costimulatory molecule, n (%) | |
| CD28 | 11 (27.5) |
| 4-1BB | 29 (72.5) |
| Treatment characteristics | |
| CAR T-cell dose, n (%) | |
| (1-2) ×106 cells per kilogram | 21 (52.5) |
| (1-2) ×107 cells per kilogram | 19 (47.5) |
| CRS grade, n (%) | |
| No grade | 1 (2.5) |
| 1-2 | 33 (82.5) |
| 3-5 | 6 (15) |
| Neurotoxicity grade, n (%) | |
| No grade | 28 (70) |
| 1-2 | 12 (30) |
| 3-5 | 0 |
| Corticosteroids, n (%) | 12 (30) |
| Tocilizumab, n (%) | 11 (27.5) |
| Response, n (%) | |
| CR/sCR | 31 (77.5) |
| VGPR | 5 (12.5) |
| PR | 4 (10) |
| Characteristic . | All patients (n = 40) . |
|---|---|
| Baseline characteristics | |
| Age, years, median (range) | 55 (27-70) |
| Male gender, n (%) | 27 (67.5) |
| Subtype (monoclonal globulin), n (%) | |
| IgG | 17 (42.5) |
| IgA | 11 (27.5) |
| IgD | 7 (17.5) |
| Light chain | 5 (12.5) |
| ISS stage, n (%) | |
| I | 15 (37.5) |
| II | 13 (32.5) |
| III | 12 (30) |
| Previous therapy lines, median (range) | 4 (2-9) |
| CAR T-cell costimulatory molecule, n (%) | |
| CD28 | 11 (27.5) |
| 4-1BB | 29 (72.5) |
| Treatment characteristics | |
| CAR T-cell dose, n (%) | |
| (1-2) ×106 cells per kilogram | 21 (52.5) |
| (1-2) ×107 cells per kilogram | 19 (47.5) |
| CRS grade, n (%) | |
| No grade | 1 (2.5) |
| 1-2 | 33 (82.5) |
| 3-5 | 6 (15) |
| Neurotoxicity grade, n (%) | |
| No grade | 28 (70) |
| 1-2 | 12 (30) |
| 3-5 | 0 |
| Corticosteroids, n (%) | 12 (30) |
| Tocilizumab, n (%) | 11 (27.5) |
| Response, n (%) | |
| CR/sCR | 31 (77.5) |
| VGPR | 5 (12.5) |
| PR | 4 (10) |
ISS, International Staging System; PR, partial response; VGPR, very good partial response.